Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.
Zacks Investment Research on MSN
Recursion Pharmaceuticals to report Q3 earnings: What's in the cards?
Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 results on Nov. 2, 2026. The Zacks Consensus Estimate is pegged at a loss of 24 ...
Salt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering ...
Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from ...
Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial ...
Richard Socher's Recursive has committed about two-thirds of its $650m raise to a single multi-year AWS contract, staffing like a seed startup while buying compute like a frontier lab. And it says ...
Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an optimistic sentiment. The company is experiencing strong leadership transitions, maintaining a robust financial ...
Recursion Pharmaceuticals, Inc. (RXRX), the self-styled "clinical-stage TechBio company with a mission to decode biology to radically improve lives" (Source: 2025 annual report/10-K filing), reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results